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Immunosuppression resulting from HIV infection increases the risk of progression to active tuberculosis (TB) both in individuals newly
exposed to Mycobacterium tuberculosis (MTB) and in those with latent infections. We hypothesized that HIV-positive individuals who do
not develop TB, despite living in areas where it is hyperendemic, provide amodel of natural resistance.We performed a genome-wide asso-
ciation study of TB resistancebyusing 581HIV-positiveUgandans andTanzanians enrolled inprospective cohort studies of TB; 267 of these
individuals developedactiveTB, and314didnot.A commonvariant, rs4921437at5q33.3,was significantly associatedwithTB (odds ratio¼
0.37, p ¼ 2.113 108). This variant lies within a genomic region that includes IL12B and is embedded in an H3K27Ac histone mark. The
locusalsodisplaysconsistentpatternsof linkagedisequilibriumacrossAfricanpopulationsandhas signalsof strong selection inpopulations
from equatorial Africa. Along with prior studies demonstrating that therapy with IL-12 (the cytokine encoded in part by IL12B, associated
with longer survival followingMTB infection inmice deficient in CD4 Tcells), our results suggest that this pathwaymight be an excellent
target for the development of newmodalities for treating TB, especially for HIV-positive individuals. Our results also indicate that studying
extreme disease resistance in the face of extensive exposure can increase the power to detect associations in complex infectious disease.Introduction
Mycobacterium tuberculosis (MTB) and HIV are major causes
of infectious-disease mortality worldwide.1,2 In 2014, more
than 25% of the 1.5 million people who died from active
tuberculosis (TB) were HIV positive, and the great majority
were in sub-Saharan Africa.1,2 The immunosuppression re-
sulting fromHIV infection increases the risk of progression
of an MTB infection to active disease both in individuals
newly exposed to MTB and in those with latent infec-
tions.3,4
Various approaches to studying the relationship be-
tween host genetics and TB, including genome-wide asso-
ciation studies (GWASs) in sub-Saharan Africa, have been
published.5–7 The GWAS results have not explained a
substantial portion of the genetic risk, possibly owing to
the cross-sectional ascertainment of control individuals,
which does not guarantee MTB exposure; this will most
likely reduce estimated effect sizes as a result of increased
noise. These studies compared immunocompetent case
and control individuals in search of common variation
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cohorts at extreme risk and focus on genetic factors that
prevent the development of active disease despite this
increased vulnerability.
All previous studies of human genetic susceptibility to TB
have used HIV-seropositive status as an exclusion criterion
or adjusted for it as a potential confounder in the ana-
lyses.6–9 Here, we hypothesized that HIV-positive individ-
ualswhodonot developTB, despite living in areas hyperen-
demic for MTB, are highly resistant. Using prospective
cohorts of TB in East Africa, we compared this extreme
control group toHIV-positive individualswith TB.We iden-
tified a genome-wide-significant variant in a regulatory
region near IL12B (MIM: 161561), a gene involved in cell-
mediated immunity against intracellular bacteria.Subjects and Methods
Study Populations
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available for most variables. All individuals who participated in
our study provided written informed consent.
Tanzania
Participants were recruited from the extended follow-up cohort
of the DarDar vaccine trial. This cohort has been previously
described.10 In brief, the DarDar trial was a randomized double-
blind phase 3 trial of an inactivated whole-cell mycobacterial
vaccine (SRL 172). Subject enrollment occurred between 2001
and 2005, and the study was concluded in 2008. All enrolled indi-
viduals were HIV-positive adults (>18 years old) with a CD4
count > 200 cells/ml, had a Bacille Calmette-Gue´rin childhood
vaccination scar, and were TB negative at the time of enrollment.
The final study population consisted of 1,007 individuals in the
placebo arm and 1,006 in the vaccine group. Participants were
routinely followed up every 3 months and evaluated for active
TB through a physical examination, a chest radiograph, sputum
samples for culture and acid-fast bacilli (AFB) stain, and phlebot-
omy for an automatedmycobacterial blood culture. At the conclu-
sion of the study, a cohort of 800 total participants in both the pla-
cebo and vaccine armswere selected for extended follow-up. These
individuals have been evaluated for active TB once a year since the
conclusion of the study. We recruited 304 of the extended-follow-
up participants between September and December 2013 during
their routine visits. 36 of the individuals had been diagnosed
with definite or probable TB since the onset of the trial. Diagnostic
criteria are described in von Reyn et al.10 Individuals who did not
develop TB during follow-up but stated that they had previous
active TB were excluded from the study because those diagnoses
could not be confirmed (exclusion criteria and the remaining sam-
ple size are provided in Table S1A). As with most genetic associa-
tion studies of TB, it was not possible to determine with certainty
whether our control subjects were exposed to MTB during the
course of the study. However, such exposure in Dar es Salaam is
highly likely. This conclusion is based on the length of follow-
up (at least 8 years) and the high prevalence of TB in Tanzania,
which is among the highest in the world at 528 per 100,000 indi-
viduals.11 Additionally, this prevalence estimate is based on a
country average, and it has been shown that such national-surveil-
lance values underestimate urban incidence.12
We also used previously collected samples from the DarDar
nutrition study in Dar es Salaam, Tanzania.13 The DarDar nutri-
tion study was a randomized, controlled trial assessing the effec-
tiveness of a protein-calorie supplement (PCS) on standard TB
and HIV treatment in women. All enrolled women were HIV-pos-
itive adults (>18 years old) and had newly diagnosed active TB.
150 participants were randomized to either a PCS arm or a multi-
vitamin control group. Treatment protocols recommended by the
World Health Organization were followed through the Tanzanian
Ministry of Health National Tuberculosis and Leprosy Program.
Subjects were followed monthly until the completion of the study
in 2014. Available samples from 85 participants of the DarDar
nutrition study were used.
Uganda
We used samples from participants of the household-contact
(HHC) study conducted in Kampala, Uganda, from 2002 to 2014.
This cohort has been previously described.14,15 In brief, the HHC
combined case-control and family-based designs to analyze the ge-
netic epidemiology of TB. Individuals diagnosed with new active
TB were referred to the study through the Uganda National Tuber-
culosis and Leprosy Programme, and those who consented were
enrolled as index subjects. Relatives and unrelated individuals
living within the same household were subsequently enrolledThe Ameandevaluated for activeTB, latentTB, andHIV.Both indexand inci-
dent subjects of active TB were given the recommended therapy.16
Importantly, selecting our TB case and control individuals from the
incident contacts guaranteed exposure of the control individuals
because of their proximity to the index individuals.14We analyzed
samples from a subset of 263 HIV-positive individuals. To assure a
similar age distribution between the Ugandan and Tanzanian co-
horts, we removed individuals under the age of 18 years from the
analysis. Also, individualswhodidnot developTBduring the study
follow-upbut stated that theyhadprevious activeTBwere removed
(Table S1A). Data for 69 previously genotyped samples from HIV-
positive individuals from this cohort were also available. To deter-
mine whether HIV status of the original index individuals affected
TB transmissibility, we evaluated whether the HIV status of index
individuals in the entire HHC study associated with TB status in
the contacts, and it did not (p ¼ 0.91).
Equatorial African Populations Used in Selection Analyses
Individuals from a previous study of six populations in Cameroon
were included in this study (n ¼ 125).17 The Baka (n ¼ 25),
Bakola (n ¼ 29), and Bedzan (n ¼ 13) are Niger-Kordofanian
Bantu-speaking Western Pygmy hunter-gatherer populations. The
Ngumba (n ¼ 20), Southern Tikar (n ¼ 19), and Lemande (n ¼ 19)
are neighboring Niger-Kordofanian Bantu-speaking agricultural
populations. Data were also available for 12 Yoruba individuals
living in Nigeria. The Yoruba participants were analyzed with the
Ngumba, Southern Tikar, and Lemande groups as a Niger-Kordofa-
nian-West population sample. An additional 18 Datog from
Tanzania comprised the third equatorial African grouping.
These studies were approved by the institutional review boards
at Muhimbili University for Health and Allied Sciences, Dart-
mouth College, Uganda National Council for Science and Tech-
nology, University Hospitals of Cleveland, and the University of
Pennsylvania for the appropriate samples.DNA Isolation and Genotyping
For participants from the DarDar vaccine trial, 5 ml of whole blood
was drawn into EDTA-coated tubes (BD Biosciences) and immedi-
ately stored at 4C. DNA was extracted the day of the phlebotomy
with the Gentra Puregene Blood Kit (QIAGEN) in accordance with
the manufacturer’s recommendations in Dar es Salaam. For partic-
ipants of the DarDar nutrition and HHC studies, buffy coats were
isolated on site and shipped to Dartmouth College for DNA extrac-
tion. DNA was isolated from buffy coats with the QIAamp
DNA Blood Mini Kit (QIAGEN). All DNA samples were stored
at 80C prior to genotyping.
All available samples from theDarDar vaccine trial (n¼ 304), the
DarDar nutrition study (n¼ 85), and theHHC study (n¼ 263)were
selected for genotyping. DNA quality was evaluated according to
the 260/280 ratio with a NanoDrop 2000 spectrophotometer
(ThermoScientific) and anelectrophoresis quality score.After qual-
ity control, a total of 639 samples were genotypedwith the Human
Core ExomeBeadChip (542,585 SNPs) at theHussman Institute for
Human Genetics in Miami. After applying the exclusion criteria
of adult age (R18 years old) and no history of prior active TB,
we analyzed the remaining participants, who consisted of 283 par-
ticipants from the DarDar vaccine trial, 75 participants from the
DarDar nutrition study, and 234 participants from the HHC study
(Table S1A). SNPs with a genotyping call rate > 0.95 and a Hardy-
Weinberg equilibrium p value > 1.00 3 104 were retained. All re-
maining participants had a per-individual genotyping call rate >
0.95. A sex check was performed, and cryptic relatedness wasrican Journal of Human Genetics 98, 514–524, March 3, 2016 515
evaluated in PLINK (v.1.07).18 From each pair of related study par-
ticipants, one individual was randomly removed (pi-hat > 0.20).
The final study population genotyped on the Exome BeadChip
included 278 participants from the extended follow-up of the
DarDar vaccine trial, 65 participants from the DarDar nutrition
study, and 213 participants from the HHC study.
Samples from 64 additional HIV-positive Ugandan HHC partici-
pants were genotyped with an Illumina HumanOmni5-Quad
BeadChip (4.8 million SNPs). DNA was extracted from buffy coats
with the QIAamp DNA Mini Kit (QIAGEN) and quantified with
NanoDrop and Qubit. Genotyping and DNA quality checking
weredoneat theGenomicsCore atCaseWesternReserveUniversity.
Further quality-control steps for samples included checking for sex-
mismatcherrors, relationship errors (within the larger dataset of 483
samples), consistency of blind duplicates, call rate (>95%), tenth
percentile GenCall score (>0.42), visual inspection of the B-allele-
frequency plot of samples with a <98% call rate, and unusually
highautosomalheterozygosity. Individuals<18years old and those
related to the participants genotypedwith the ExomeBeadChip (pi-
hat > 0.20) were excluded. 25 of the additional 64 individuals re-
mained after we applied these exclusion criteria.
For the samples used in the selection analyses, after phlebot-
omy, white blood cells were isolated by a modified salting-out pro-
cedure,19 and DNAwas extracted with a Puregene DNA Extraction
Kit (Gentra Systems).17 The samples were genotyped with the Illu-
mina Human 1M-Duo BeadChip.17 We evaluated cryptic related-
ness by randomly removing individuals with pi-hat > 0.25, and
we removed SNPs with call rates less than 95%. All quality-control
measures were done in PLINK (v.1.07).18 Admixture was evaluated
by principal-component analysis in R20 and STRUCTURE as previ-
ously described.17Immunological Data
Enrollment CD4 counts were available for 437 subjects, including
all participants of the extended follow-up of the DarDar vaccine
trial and nutrition study andHHC study participants who enrolled
after 2004. CD4 counts were not ascertained for individuals who
entered the HHC study before 2004 (n ¼ 144) because antiretrovi-
ral therapy was unavailable in Uganda before then.
All participants of the DarDar nutrition study were affected by
TB, and the design of the HHC study guaranteed exposure to
MTB. To address possible confounding of our results by exposure
in the extended follow-up of theDarDar vaccine trial, we leveraged
available interferon-g (IFN-g) release assay (IGRA) data. Immune
response to Mycobacteria was assessed with an IFN-g ELISA, a triti-
ated thymidine lymphocyte proliferation assay (LPA), and ELISA
for antibodies to the MTB glycolipid lipoarabinomannan (LAM).
The assays used in this study have been previously described.21 In
brief, IFN-g and LPA assays used four different antigens in the sam-
ples fromTanzania:Mycobacteriumvaccae sonicate (2mcg/ml),MTB
antigen85 (Ag85; 1mcg/ml),MTB early secretory antigenic target 6
(ESAT-6; 2 mcg/ml), and MTB whole-cell lysate (1 mcg/ml).21
Media alone served as a negative control, and phytohemagglutinin
(2.5 mcg/ml; Sigma) was used as a positive control.21Statistical Analyses
Logistic regression in PLINK (v.1.07)18 was used for testing the as-
sociation between single SNPs in an additive model and active TB
case-control status. A priori power analyses in QUANTO revealed
that a minor allele frequency (MAF) > 0.20 should be used in
both cohorts in the single-SNP association analyses.22 Summary516 The American Journal of Human Genetics 98, 514–524, March 3statistics for available covariates were calculated in STATA
(v.11.2).23 Covariate data were analyzed for differences between
TB case and control individuals. For categorical variables, analyses
were performed with c2 tests. For continuous variables, either
t tests or non-parametric Wilcoxon rank-sum tests were used,
where appropriate. Covariates significantly associated with case-
control status were included in the final models (Tables S1B–
S1E). Vaccine status did not associate with active TB in the volun-
tary DarDar extended follow-up (p value ¼ 0.122; Table S1B);
therefore, it was not adjusted for.
Because the Tanzanian cohorts were recruited in Dar es Salaam
and the Ugandan cohort was recruited in Kampala, both large ur-
ban centers, admixture was a likely confounder in this study. To
adjust for population structure within each country, we used the
SNPRelate package in R20,24 to calculate principal components
separately for participants from Uganda and Tanzania by using
SNPs with r2 < 0.1, a MAF > 0.2, and a genotype call rate >
0.95. Analyses of the combined cohorts were also adjusted for
country of origin. Data on self-reported tribal identity were avail-
able for the individuals from Uganda. The first, sixth, and seventh
principal components were significant in predicting membership
from the predominant tribe, Muganda (63% of the participants),
versus all others. Because self-described ethnicity was not available
for Tanzania, we conservatively chose to use ten principal compo-
nents (Table S2). We used locus zoom to plot the region of the SNP
with the strongest association25 (Figure 1). SNPs in the region
of interest (rs4921437 position 5 1 Mb) were imputed with
IMPUTE2 (v.2.3.1) and one multi-population phased reference
panel from the 1000 Genomes Project.26–28
We performed logistic-regression analysis of TB in the combined
cohortwhile adjusting forCD4count at enrollment, sex, countryof
origin, and ten principal components in 437 individuals for whom
CD4 data were available (Table S3A). To assess the effect of variable
immunosuppression of case and control individuals on the associ-
ation results, we repeated this analysiswithout adjustment for CD4
counts in the same subset of individuals (Table S3B).We performed
logistic-regression analyses of TBwith IGRA results in the extended
follow-up of the DarDar vaccine trial (Table S4).
We examined all pairwise haplotypes within the locus of inter-
est, i.e., the region that included our most significant SNP,
rs4921437. The additional SNPs were selected on the basis of
MAF > 0.05. 11 unimputed SNPs passed quality control and
spanned IL12B and UBLCP1 (MIM: 609867), and we used these
to test for haplotype association (Figures S1A and 1B). This region
was defined with Haploview.29 We performed haplotype associa-
tion analyses with UNPHASED (v.3.1.7)30 while adjusting for the
same covariates as in the single-SNP association analyses. We
then performed a single three-SNP haplotype analysis with SNPs
from the two most significant pairwise haplotypes (Table S5).
Additionally, for each cohort, we used a c2 test in STATA
(v.11.2)23 to compare haplotypes from the case group only, the
control group only, and the entire dataset to corresponding haplo-
types in phase 3 samples of the HapMap Project.31,32 MAFs were
obtained from the 1000 Genomes Project and the Human
Genome Diversity Project.26,33,34
Selection Analysis
Phase was inferred with the Beagle software package.35 Using
LDhat (v.2.1), we generated fine-scale recombination maps with
25 males and 25 females from each of the following groups: unre-
lated individuals from two HapMap3 release 2 populations,32
Yoruba from Ibadan, Nigeria (YRI), and Luhya from Webuye,, 2016
Figure 1. Results for Imputed SNPs in a 50 kb Region around rs4921437 from an Additive Genetic Model for Association with TB in
the Combined Cohort
The imputed SNPwith themost significant association, rs10515780, is in a purple. Colors represent LD (measuredwith r2) between avail-
able variants and rs10515780. Annotation of chromatin-state segmentation in the zoomed region around rs4921437 is from the UCSC
Genome Browser (hg19) for nine human cell types (chr5: 158,680,000–158,700,000). Bright red indicates an active promoter, light red
indicates a weak promoter, yellow represents a weak or poised enhancer, light green represents a weak transcribed state, and dark green
indicates transcriptional transition or elongation. An H3K27Ac histone mark aligns with the most significant SNPs.Kenya (LWK).36 All ancestral alleles for the SNPs included in this
analysis were established with genome-wide sequences of non-
human primates, chimpanzee, orangutan, and rhesus macaque,
downloaded from the UCSC Genome Browser.37 Approximately
5% of available SNPs could not be assigned an unambiguous
ancestral state and were thus removed prior to selection analysis,
as were SNPs with a MAF < 0.05.38 Selection was assessed with
the integrated haplotype score (iHS) test statistic, as described
by Voight et al.38 iHS values were standardized to a mean of
0 and a unit variance with respect to SNPs with similar derived
allele frequencies.38 iHS values in the top 0.1% of the distribution
of absolute values were considered top candidates for selection.The AmeFunctional Annotation
The ENCODE Project39 was accessed via the UCSC Genome
Browser,37 and data provided by the Bernstein lab were used for
functional annotation.Results
The combined study population consisted of 267 individ-
uals with TB (100 from Tanzania and 167 from Uganda)
and 314 control individuals (243 from Tanzania and 71
fromUganda; Table S1). Male gender associated with activerican Journal of Human Genetics 98, 514–524, March 3, 2016 517
Table 1. SNPs Associated with Active TB at p < 5.00 3 105
SNP Chr Minor Allele MAF OR 95% CI p Value Gene
Uganda
rs4921437 5 T 0.210 0.279 (0.167, 0.467) 1.18 3 106 UBLCP1, IL12B
rs7297313 12 C 0.337 0.349 (0.22, 0.555) 8.6 3 106 GRIN2B
rs859063 1 G 0.345 3.057 (1.82, 5.135) 2.40 3 105 SLC44A3
Tanzania
rs2681052 7 T 0.387 2.649 (1.717, 4.087) 1.07 3 105 THSD7A
rs17048476 3 A 0.419 2.433 (1.618, 3.657) 1.91 3 105 AK124857
rs2587469 10 C 0.457 0.423 (0.284, 0.63) 2.26 3 105 ADAMTS14
rs9893385 17 G 0.467 0.414 (0.275, 0.622) 2.26 3 105 ABCA8
rs3860173 9 T 0.361 2.276 (1.556, 3.329) 2.27 3 105 RGS3
rs1524713 1 T 0.277 2.427 (1.595, 3.693) 3.47 3 105 DAB1
rs2807348 1 C 0.255 0.354 (0.217, 0.579) 3.48 3 105 WNT4
rs4700255 5 G 0.323 2.337 (1.56, 3.502) 3.87 3 105 ACTBL2
rs16870583 5 C 0.251 2.317 (1.549, 3.466) 4.35 3 105 IRX2
rs930205 5 G 0.294 2.393 (1.572, 3.642) 4.64 3 105 SH3TC2
rs557438a 5 T 0.368 0.412 (0.269, 0.632) 4.70 3 105 MCC
rs4921437 5 T 0.209 0.484 (0.296, 0.792) 3.84 3 103 UBLCP1, IL12B
Combined Cohorts
rs4921437 5 T 0.209 0.374 (0.266, 0.528) 2.11 3 108 UBLCP1, IL12B
rs8028149 15 C 0.416 0.509 (0.385, 0.672) 1.96 3 106 VPS13C
rs1616723 6 G 0.201 0.439 (0.309, 0.624) 4.13 3 106 GLO1
rs955263 4 T 0.343 1.848 (1.391, 2.454) 2.26 3 105 SORBS2
rs12636260 3 T 0.257 1.977 (1.442, 2.709) 2.26 3 105 ZPLD1b
rs4768760 12 C 0.407 0.562 (0.429, 0.735) 2.57 3 105 SLC38A4
rs844669 7 G 0.301 0.521 (0.385, 0.707) 2.68 3 105 CALN1
rs4236914 8 T 0.237 1.912 (1.412, 2.591) 2.84 3 105 SFRP1
rs4860106 4 G 0.460 0.580 (0.449, 0.749) 3.03 3 105 LPHN3
rs1482868 6 T 0.279 0.544 (0.407, 0.728) 4.29 3 105 F13A1
rs2346943 16 G 0.326 1.793 (1.354, 2.373) 4.48 3 105 RBFOX1
Results are presented for the Ugandan cohort, the Tanzanian cohorts, and the combined cohorts. All analyses were adjusted for principal components and sex; the
combined analyses were also adjusted for country of origin. Abbreviations are as follows: Chr, chromosome; CI, confidence interval; MAF, minor allele frequency;
and OR, odds ratio.
aOther SNPs between rs557438 and rs4921437 are statistically significant but are not relevant here.
bClosest protein-coding gene.TB in univariate logistic regression (odds ratio [OR] ¼ 1.78,
95% confidence interval [CI] ¼ 1.23–2.57, p ¼ 0.002). Age
did not significantly associate with TB (p ¼ 0.186).
Using logistic regression,weobservedagenome-wide-sig-
nificant association between common variant rs4921437
and TB (OR ¼ 0.37, 95% CI ¼ 0.27–0.53, p ¼ 2.11 3 108;
Table 1 and Figure S2A). Results were consistent when the
samples were stratified by country (Uganda: OR ¼ 0.28,
95% CI ¼ 0.17–0.47, p ¼ 1.18 3 106; Table 1; Tanzania:
OR ¼ 0.48, 95% CI ¼ 0.30–0.79, p ¼ 3.84 3 103; Table 1518 The American Journal of Human Genetics 98, 514–524, March 3and Figures S2B and S2C). The genomic inflation factor (l)
for the final adjusted logistic-regression model was 1.029
for analysis of the cohorts combined, 1.023 for analysis of
samples from Tanzania, and 1.056 for analysis of samples
fromUganda. The cluster plot for rs4921437 shows that ge-
notype calling for this SNP was unambiguous for virtually
all samples (Figure S3). These results indicate not only
that the combined association is highly significant but
also that each cohort alone provides strong evidence of
association; rs4921437 was the most significant SNP in, 2016
Uganda and was among the most significant in Tanzania
(Figures S2A–S2C).
We imputed all SNPs within 1Mb of rs4921437. Imputed
variant rs10515780, only 842 bp from rs4921437, dis-
played the most significant association with TB (combined
cohort OR ¼ 0.34, 95% CI ¼ 0.24–0.49, p ¼ 6.21 3 109;
Figure 1 and Table S6). This SNP was in very high linkage
disequilibrium (LD) with the index SNP (D0 ¼ 1 in both
cohorts, r2 ¼ 0.84 in Tanzania and 0.89 in Uganda) and
was imputed with a high degree of certainty (imputation
certainty was 0.993 in both Tanzania and Uganda).
Variants rs4921437 and rs10515780 map to an intron in
UBLCP1, ubiquitin-like-domain-containing C-terminal
domain phosphatase 1. Variant rs4921437 is 51 kb away
from the 30 UTR of IL12B. According to ENCODE,39 both
rs4921437 and rs10515780 are located in an H3K27Ac his-
tone mark that most likely represents a regulatory region
(Figure 1).
Adjustment for CD4 counts in the subset of participants
for whom we had data (n ¼ 437) demonstrated that vari-
able immunosuppression among case and control individ-
uals was not a confounding factor (Table S3). Prior MTB
exposure of the control group is essential, and our cohorts
virtually assured it. All individuals from the DarDar nutri-
tion study were affected by TB. The HHC study design gua-
rantees exposure of the TB-negative individuals to MTB,
given that co-habitation with an individual with active
TB was a prerequisite for enrollment. Although direct con-
tact with index individuals with active TB was not assessed
in the DarDar vaccine trial, 8 years had elapsed between
the completion of enrollment for the vaccine trial and
recruitment into our study, and TB prevalence in Tanzania
is among the highest in the world (see Subjects and
Methods). Therefore, participants were both HIV positive
and living in an area hyper-endemic for TB at least this
long, virtually guaranteeing MTB exposure. Nevertheless,
to address possible confounding by lack of exposure, we as-
sessed response of IGRAs and LPAs by case-control status
and observed no statistically significant differences (Table
S4). Although the Ugandan and Tanzanian studies were
designed differently, the consistency in genetic association
results underscores the robustness of this finding.
Analysis of the UBLCP1-IL12B region in the unimputed
dataset revealed blocks of LD between rs4921437 and
SNPs in IL12B in the Ugandan and Tanzanian cohorts,
as well as in African samples from phase 3 of the
HapMap Project (Figure S1). A three-variant haplotype of
rs4921437, rs4921468 (intergenic), and rs3213094 (intronic
in IL12B) had a more significant association with TB than
rs4921437 alone in the combined cohort (p ¼ 4.56 3
1015) (Table S5). Results were consistent when the Ugan-
dan and Tanzanian cohorts were analyzed separately
(p ¼ 1.98 3 1011 and 4.56 3 105, respectively). When
we conditioned an rs4921468-rs3213094 haplotype anal-
ysis on the main-effect variant, rs4921437, the combined
cohort haplotype association was significant at a multiple-
testing-corrected threshold based on thenumber of SNPs re-The Amemaining after quality control (p value 1.19 3 107;
threshold for 175,906 variants ¼ 2.843 107).
Frequencies of the three-variant haplotype were not
significantly different between the Ugandan and Tanza-
nian cohorts, nor among founders of the LWK or ASW (Af-
rican ancestry in Southwest USA) from phase 3 of HapMap
(Table S7).32 This conservation of haplotype frequencies
among these Africa-derived samples was unexpected given
the known diverse history of these populations and
genomic differentiation between them.40 Frequencies of
the three-variant haplotype in Uganda and Tanzania
were significantly different from those in all other
HapMap phase 3 populations (Table S7).32
We assessed whether allele-frequency distributions were
consistent with selection. The ancestral, minor allele of
rs4912437 (T), which associated with TB resistance, had
a MAF of 0.21 in our combined cohort (0.21 in both
Tanzania and Uganda). In the African, European, and
South Asian origin populations from phase 3 of the
HapMap Project and the 1000 Genomes Project, the
T allele frequency varied between 0.11 and 0.36 (Table
S8).32 The MAFs in the Biaka Pygmy and Mbuti Pygmy
populations of the Human Genome Diversity Project
were 0.45 and 0.46, respectively. Of note, the ancestral
variant had a very low frequency in East Asian populations
for which data are available (MAF < 0.025), suggesting
either a loss due to drift or its maintenance due to selection
where the allele remained.
We found highly similar LD patterns over the entire
IL12B region in our Tanzanian and Ugandan cohorts
(Figure S1). Considering previously documented patterns
of less LD and greater variation of LD among African pop-
ulations,41 we did not expect to find such striking similar-
ities. We then evaluated signatures of selection by using an
iHS38 in equatorial African populations (West Pygmy,
Datog, and Niger-Kordofanian-West) for which we had
available data with coverage adequate for these ana-
lyses.42 The iHS test is most sensitive to recent adaptive
events (<25,000 years ago), appropriate here because TB-
related selective pressure is thought to have increased after
agriculture-associated growth in population density.38,42
Two intronic SNPs in IL12B (4,672 bp apart) were in the
top 0.1% of the distribution of absolute values of iHSs for
one million genotyped SNPs in at least one equatorial
African population (Table 2). The region surrounding
rs3213093 had a signature of selection in the top 0.1% of
the distribution in the Datog population sample, whereas
the region centered on rs2421047 had a signature of selec-
tion in the top 0.1% of the distribution in the Niger-Kordo-
fanian-West population samples (Table 2). In our study co-
horts, rs3213093 and rs2421047 were in high LDwith each
other (D0 ¼ 0.98–1.0) and with rs4921437 (D0 ¼ 0.79–0.92)
(Figure S4). The iHS values of rs4921437 in the Datog,
Western Pygmy, and Niger-Kordofanian-West populations
were not in the top 0.1% of the respective distributions.
We replicated several variants that have been previ-
ously reported to associate with TB. A SNP in PTX3rican Journal of Human Genetics 98, 514–524, March 3, 2016 519
Table 2. Analyses of iHS Values
SNP
jiHSj in the
Datog
jiHSj Percentage
in the Datog
jiHSj in the Niger
Kordofanian West
jiHSj Percentage in the
Niger Kordofanian West
jiHSj in the
Western Pygmy
jiHSj Percentage
in the Western Pygmy
rs3213093 3.915 0.054% 3.591 0.104% 2.599 1.23%
rs2421047 3.088 0.371% 3.616 0.097% 2.636 1.13%
rs4921437 0.391 68.84% 0.742 45.40% 0.997 31.44%
Absolute values of normalized iHS values are provided for two IL12B SNPs that were in the top 0.1% of the jiHSj distribution in any of the available equatorial
African populations. Also shown are the percentages and corresponding values for rs4921437. The following abbreviation is used: iHS, integrated haplotype score.(MIM: 602492), rs3816527, associated with TB at a
p value of 4.69 3 104. This SNP is 715 bp away from
rs1840680, a previously associated variant in a West Afri-
can population,43 and it is in strong LD with it in the
LWK 1000 Genomes population (r2 ¼ 0.86). We imputed
rs1840680, and it associated with a p value of 0.0013 and
an OR of 1.63 (Table 3). Variants rs2057178, rs4331426,
and rs4733781, which previously associated with TB
in genome-wide analyses, had ORs similar to those
previously reported (rs2057178: OR ¼ 0.84 in our com-
bined cohort versus 0.77 in Thye et al.6; rs4331426:
OR ¼ 1.16 in our combined cohort versus 1.18 in Thye
et al.7; and rs4733781: OR ¼ 0.92 in our combined cohort
versus 0.84 in Curtis et al.5). However, our sample size
was smaller than those in the reported studies, and the
SNPs were not significant in our analyses (Table 3). These
results, even though not significant, support the validity
of our cohort design and phenotype definitions.Discussion
Our approach to the study of TB genetics focuses on resis-
tance as opposed to susceptibility. Specifically, we hypothe-
sized that HIV-immunocompromised individuals who
resist TB despite prolonged exposure represent an extreme
phenotype that canprovidenew insights intoTBpathogen-
esis. We identified a region encompassing IL12B, a gene
originally shown to underpin a very raremonogenic immu-
nodeficiency that promotes high susceptibility to several
mycobacterial infections.44 Unlike Mendelian immunode-
ficiency-causing mutations identified in subjects present-
ing with hyper-susceptibility to infection, resistance vari-
ants only emerge as conferring noticeable protection in
high-risk yet disease-free subjects. OurHIV-positive cohorts
enabled us to find a variant that has amuch larger effect size
than previously associated common SNPs, one detected
with a sample size well below that of most published
GWASs. Also, in contrast to most previous TB association
studies that have used cross-sectional selection of the con-
trol group, in our study the control individuals were ascer-
tained as part of long-term, well-characterized, prospective
cohorts. This is a distinct strength of our design; individuals
were routinely tested for TB. Furthermore, in the subset
of individuals for whom CD4-count data and IGRA data
were available, we did not observe any confounding by
extent of immunosuppression or exposure to MTB.520 The American Journal of Human Genetics 98, 514–524, March 3Our SNP of primary interest is located in an area
enriched with a histone acetylation mark often found in
active regulatory elements, suggesting functionality. The
H3K27Ac annotation indicates a modification that acts
in concert with an H3K4Me1 mark to differentiate active
enhancer elements from poised or inactive ones.45,46
Such chromatin modifications are associated with higher
regulatory responses at enhancer transcription factor bind-
ing sites,45 possibly potentiating the effect of DNA poly-
morphisms in the region.
The variants with the strongest association with TB are
located in introns ofUBLCP1, previously shown to regulate
nuclear proteasome activity.47 Variants in this gene have
been previously associated with carotid stenosis,48 psoria-
sis,49 and platelet aggregation.50 Importantly, these SNPs
are also in proximity to IL12B, a gene previously associated
with both TB9,51 and leprosy.52 IL12B variants have also
been associated with carotid stenosis53 and psoriasis,54
possibly owing to LD with SNPs in UBLCP1. IL12B encodes
p40, one of two subunits of interleukin-12 (IL-12)55 and IL-
23.56 IL-12 is a cytokine secreted by phagocytes and den-
dritic cells, and it causes differentiation of naive T cells
into T helper 1 (Th1) cells and stimulates IFN-g production
from T cells and natural killer cells.57,58 In experimental
models, IL-12 restricted MTB proliferation throughout
the course of infection and was a necessary factor in gran-
uloma formation and antigen-specific delayed-type hyper-
sensitivity.59–61 Previous studies in humans have reported
associations between IL-12 deficiency and predisposition
to infections withMycobacteria but have not demonstrated
strong association with common functional variation.8,62
IL-23 also plays a role in controlling MTB infection; it is
essential for the differentiation of naive T cells into Th17
cells, which are responsible for the production of IL-17.63
IL-17 is necessary for the targeting of neutrophils to
the site of infection, and IL-17-deficient mice are unable
to control highly virulent MTB strains.63,64 Therefore,
although our analyses do not provide direct evidence of as-
sociation with IL12B, it remains a gene of substantial inter-
est on the basis of both our results and prior data relating
this locus to TB and related phenotypes.
Additional evidence supporting the detected association
derives from the high concordance of LD patterns across
several African-descent populations in the IL12B region.
Analyses using other sub-Saharan populations demon-
strated that the IL12B region has undergone positive
selection. These results demonstrate strong selection in, 2016
Table 3. Logistic-Regression Results for SNPs Reported in Other TB Studies
SNP Study Chr Minor Allele n OR 95% CI p Value Gene
rs2057178 Thye et al.6 11 A 581 0.836 (0.64, 1.10) 0.2004 WT1
rs4331426 Thye et al.7 18 G 556 1.162 (0.68, 1.51) 0.259 GATA6
rs4733781a Curtis et al.5 8 C 581 0.916 (0.67, 1.25) 0.578 ASAP1
rs1840680a Olesen et al.43 3 A 556 1.635 (1.21, 2.21) 0.0013 PTX3
Results are from the combined cohort, adjusted for principal components, sex, and country of origin. Abbreviations are as follows: Chr, chromosome; CI, confi-
dence interval; and OR, odds ratio.
aImputed genotypes.the region of interest in populations related to our study co-
horts, although the selection signature appears to be stron-
gest within IL12B and not in the regulatory region inwhich
rs4921437 is located. This lower value might be due to the
SNP location, near the end of the UBLCP1-IL12B haplotype
block.38 Because the IL12B locus has pleiotropic effects, we
cannot rule out that other historical intra-cellular patho-
gens, such as Plasmodium falciparum or Yersinia pestis,65
have exerted selective pressure on this gene.
The high prevalence of HIV-MTB co-infection in sub-
Saharan Africa, along with persisting rates of multi-drug-
resistant TB, necessitates development of new treatment
modalities tailored to this population.2 Previous studies
of exogenous IL-12 administration in murine models
have shown efficacy in limiting disease progression.
Cooper et al. demonstrated that survival of MTB-infected
mice with severe combined immunodeficiency was
extended with IL-12 treatment.66 Nolt et al. reported
improved survival, diminished bacterial loads, and
decreased pulmonary inflammation in CD4-deficient
mice 8 weeks after IL-12 therapy.67 Reduced granuloma for-
mation and decreased inflammation were also observed in
the lungs of wild-type mice.67 The strong association be-
tween TB and a common variant near the gene encoding
an IL-12 subunit in an HIV-positive host population links
the murine observations to the human phenotype. IL-12
andmembers of its pathway are therefore promising candi-
dates for development of new TB treatments, which could
be efficacious in both HIV-positive individuals and the
general population.
In conclusion, we have identified a locus conferring
strong resistance to TB, thereby demonstrating that use of
extreme phenotypes can be a powerful strategy for unravel-
ing the host genetics of complex infectious diseases. This
approach reduces the noise caused by both phenotypic
and genetic heterogeneity, allowing detection of signals
frommajor genes even in seemingly underpowered studies.Accession Numbers
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